Resveratrol treatment does not reduce arterial inflammation in males at risk of type 2 diabetes: a randomized crossover trial

Abstract

Purpose Resveratrol has shown promising anti-inflammatory effects in in vitro and animal studies. We aimed to investigate this effect on arterial inflammation in vivo.

Methods This was an additional analysis of a double-blind randomized crossover trial which included eight male subjects with decreased insulin sensitivity who underwent an ¹⁸F-fluoroxyglucose (¹⁸F-FDG) PET/CT after 34 days of placebo and resveratrol treatment (150 mg/day). ¹⁸F-FDG uptake was analyzed in the carotid arteries and the aorta, adipose tissue regions, spleen, and bone marrow as measures for arterial and systemic inflammation. Maximum target-to-background ratios (TBR_max) were compared between resveratrol and placebo treatment with the non-parametric Wilcoxon signed-rank test. Median values are shown with their interquartile range.

Results Arterial ¹⁸F-FDG uptake was non-significantly higher after resveratrol treatment (TBR_max all vessels 1.7 (1.6–1.7)) in comparison to placebo treatment (1.5 (1.4–1.6); p=0.050). Only in visceral adipose tissue, the increase in ¹⁸F-FDG uptake after resveratrol reached statistical significance (p=0.024). Furthermore, CRP-levels were not significantly affected by resveratrol treatment (p=0.091).

Conclusions Resveratrol failed to attenuate arterial or systemic inflammation as measured with ¹⁸F-FDG PET in subjects at risk of developing type 2 diabetes. However, validation of these findings in larger human studies is needed.

Zusammenfassung

Ziel Resveratrol hat in In-vitro- und Tierstudien vielversprechende anti-inflammatorische Effekte gezeigt. Unser Ziel war es, diese Wirkung auf die arterielle Entzündung in vivo zu untersuchen.

Methoden Es handelte sich um eine zusätzliche Analyse einer randomisierten Doppelblind-Crossover-Studie, an der acht männliche Probanden mit verminderter Insulinsensitivität teilnahmen, die sich nach 34 Tagen Placebo- und Resveratrol-Behandlung (150 mg/Tag) einer ¹⁸F-Fluoroxyglucose (¹⁸F-FDG)-PET/CT unterzogen. Die ¹⁸F-FDG-Aufnahme wurde in den Karotiden und der Aorta, Fettgeweberegionen, Milz und Knochenmark als Maß für die arterielle und systemische Entzündung analysiert. Die maximalen „Target-to-Background Ratios” (TBR_max) wurden zwischen Resveratrol- und Placebo-Behandlung mit dem nichtparametrischen Wilcoxon-Vorzeichen-Rang-Test verglichen. Die Medianwerte sind mit ihrem Interquartilsbereich angegeben.

Ergebnisse Die arterielle ¹⁸F-FDG-Aufnahme war nach der Resveratrol-Behandlung nicht signifikant höher (TBR_max alle Gefäße 1,7 (1,6–1,7)) im Vergleich zur Placebo-Behandlung (1,5 (1,4–1,6); p=0,050). Nur im viszeralen Fettgewebe war der Anstieg der ¹⁸F-FDG-Aufnahme nach Resveratrol statistisch signifikant (p=0,024). Auch die CRP-Werte wurden durch die Resveratrol-Behandlung nicht signifikant beeinflusst (p=0,091).

Schlussfolgerungen Resveratrol konnte die mittels ¹⁸F-FDG-PET gemessene arterielle oder systemische Entzündung bei Personen mit einem Risiko für die Entwicklung eines Typ-2-Diabetes nicht abschwächen. Allerdings ist eine Validierung dieser Ergebnisse in größeren Humanstudien erforderlich.

Schlüsselwörter

Resveratrol - arterielle Entzündung - Atheriosklerose - Positronen-Emissions-Tomografie (PET)

Keywords

resveratrol - arterial inflammation - atherosclerosis - positron emission tomography (PET)

Publication History

Received: 27 March 2021

Accepted after revision: 11 August 2021

Article published online:
16 December 2021

• References

• 1 Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506 DOI: 10.1038/nrd2060. (PMID: 16732220)
• 2 Novelle MG, Wahl D, Dieguez C. et al. Resveratrol supplementation: Where are we now and where should we go?. Ageing Res Rev 2015; 21: 1-15 DOI: 10.1016/j.arr.2015.01.002. (PMID: 25625901)
• 3 Park EJ, Pezzuto JM. The pharmacology of resveratrol in animals and humans. Biochim Biophys Acta 2015; 1852: 1071-1113 DOI: 10.1016/j.bbadis.2015.01.014. (PMID: 25652123)
• 4 Zordoky BN, Robertson IM, Dyck JR. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta 2015; 1852: 1155-1177 DOI: 10.1016/j.bbadis.2014.10.016. (PMID: 25451966)
• 5 Do GM, Kwon EY, Kim HJ. et al. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Biochem Biophys Res Commun 2008; 374: 55-59 DOI: 10.1016/j.bbrc.2008.06.113. (PMID: 18611391)
• 6 Fukao H, Ijiri Y, Miura M. et al. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Blood Coagul Fibrinolysis 2004; 15: 441-446 DOI: 10.1097/00001721-200408000-00001. (PMID: 15311151)
• 7 Vasamsetti SB, Karnewar S, Gopoju R. et al. Resveratrol attenuates monocyte-to-macrophage differentiation and associated inflammation via modulation of intracellular GSH homeostasis: Relevance in atherosclerosis. Free Radic Biol Med 2016; 96: 392-405 DOI: 10.1016/j.freeradbiomed.2016.05.003. (PMID: 27156686)
• 8 Matos RS, Baroncini LA, Precoma LB. et al. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq Bras Cardiol 2012; 98: 136-142 DOI: 10.1590/s0066-782×2012005000006. (PMID: 22231915)
• 9 Weiskirchen S, Weiskirchen R. Resveratrol: How Much Wine Do You Have to Drink to Stay Healthy?. Adv Nutr 2016; 7: 706-718 DOI: 10.3945/an.115.011627.
• 10 Ponzo V, Soldati L, Bo S. Resveratrol: a supplementation for men or for mice?. J Transl Med 2014; 12: 158 DOI: 10.1186/1479-5876-12-158. (PMID: 24893845)
• 11 Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874 DOI: 10.1038/nature01323. (PMID: 33976384)
• 12 Libby P, Ridker PM. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 2004; 116 (Suppl. 06) 9S-16S DOI: 10.1016/j.amjmed.2004.02.006. (PMID: 15050187)
• 13 Marnane M, Prendeville S, McDonnell C. et al. Plaque inflammation and unstable morphology are associated with early stroke recurrence in symptomatic carotid stenosis. Stroke 2014; 45: 801-806 DOI: 10.1161/STROKEAHA.113.003657. (PMID: 24481971)
• 14 Reeps C, Bundschuh RA, Pellisek J. et al. Quantitative assessment of glucose metabolism in the vessel wall of abdominal aortic aneurysms: correlation with histology and role of partial volume correction. Int J Cardiovasc Imaging 2013; 29: 505-512 DOI: 10.1007/s10554-012-0090-9. (PMID: 22772434)
• 15 Figueroa AL, Subramanian SS, Cury RC. et al. Distribution of inflammation within carotid atherosclerotic plaques with high-risk morphological features: a comparison between positron emission tomography activity, plaque morphology, and histopathology. Circ Cardiovasc Imaging 2012; 5: 69-77 DOI: 10.1161/circimaging.110.959478. (PMID: 22038986)
• 16 Tahara N, Kai H, Ishibashi M. et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006; 48: 1825-1831 DOI: 10.1016/j.jacc.2006.03.069. (PMID: 17084257)
• 17 Lee SJ, On YK, Lee EJ. et al. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 2008; 49: 1277-1282 DOI: 10.2967/jnumed.108.052233.
• 18 Tawakol A, Singh P, Rudd JH. et al. Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging. J Am Coll Cardiol 2014; 63: 86-88 DOI: 10.1016/j.jacc.2013.07.050. (PMID: 23973698)
• 19 Fayad ZA, Mani V, Woodward M. et al. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011; 378: 1547-1559 DOI: 10.1016/S0140-6736(11)61383-4. (PMID: 21908036)
• 20 Emami H, Vucic E, Subramanian S. et al. The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: a multicenter FDG-PET trial. Atherosclerosis 2015; 240: 490-496 DOI: 10.1016/j.atherosclerosis.2015.03.039. (PMID: 25913664)
• 21 Emami H, Singh P, MacNabb M. et al. Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans. JACC Cardiovasc Imaging 2015; 8: 121-130 DOI: 10.1016/j.jcmg.2014.10.009. (PMID: 25577441)
• 22 Kim EJ, Kim S, Kang DO. et al. Metabolic activity of the spleen and bone marrow in patients with acute myocardial infarction evaluated by 18f-fluorodeoxyglucose positron emission tomograpic imaging. Circ Cardiovasc Imaging 2014; 7: 454-460 DOI: 10.1161/CIRCIMAGING.113.001093. (PMID: 24488982)
• 23 Figueroa AL, Takx RA, MacNabb MH. et al. Relationship Between Measures of Adiposity, Arterial Inflammation, and Subsequent Cardiovascular Events. Circ Cardiovasc Imaging 2016; 9: e004043 DOI: 10.1161/CIRCIMAGING.115.004043. (PMID: 27072302)
• 24 de Ligt M, Bruls YMH, Hansen J. et al. Resveratrol improves ex vivo mitochondrial function but does not affect insulin sensitivity or brown adipose tissue in first degree relatives of patients with type 2 diabetes. Mol Metab 2018; 12: 39-47 DOI: 10.1016/j.molmet.2018.04.004. (PMID: 29706321)
• 25 Sahebkar A, Serban C, Ursoniu S. et al. Lack of efficacy of resveratrol on C-reactive protein and selected cardiovascular risk factors--Results from a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2015; 189: 47-55 DOI: 10.1016/j.ijcard.2015.04.008. (PMID: 25885871)
• 26 Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J 2014; 35: 1782-1791 DOI: 10.1093/eurheartj/ehu203. (PMID: 24864079)
• 27 Bucerius J, Vijgen GH, Brans B. et al. Impact of bariatric surgery on carotid artery inflammation and the metabolic activity in different adipose tissues. Medicine (Baltimore) 2015; 94: e725 DOI: 10.1097/MD.0000000000000725. (PMID: 25997038)
• 28 Timmers S, Konings E, Bilet L. et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab 2011; 14: 612-622 DOI: 10.1016/j.cmet.2011.10.002. (PMID: 22055504)
• 29 Tome-Carneiro J, Gonzalvez M, Larrosa M. et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol Nutr Food Res 2012; 56: 810-821 DOI: 10.1002/mnfr.201100673. (PMID: 22648627)
• 30 de Ligt M, Timmers S, Schrauwen P. Resveratrol and obesity: Can resveratrol relieve metabolic disturbances?. Biochim Biophys Acta 2015; 1852: 1137-1144 DOI: 10.1016/j.bbadis.2014.11.012. (PMID: 25446988)
• 31 Liu K, Zhou R, Wang B. et al. Effect of resveratrol on glucose control and insulin sensitivity: a meta-analysis of 11 randomized controlled trials. Am J Clin Nutr 2014; 99: 1510-1519 DOI: 10.3945/ajcn.113.082024. (PMID: 24695890)
• 32 Huang H, Chen G, Liao D. et al. The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials. Obes Rev 2016; 17: 1329-1340 DOI: 10.1111/obr.12458. (PMID: 27456934)
• 33 Liu Y, Ma W, Zhang P. et al. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 2015; 34: 27-34 DOI: 10.1016/j.clnu.2014.03.009. (PMID: 24731650)
• 34 Wilson T, Knight TJ, Beitz DC. et al. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci 1996; 59: PL15-PL21 DOI: 10.1016/0024-3205(96)00260-3. (PMID: 8684261)
• 35 Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008; 22: 659-661 DOI: 10.1096/fj.07-9574LSF. (PMID: 17942826)
• 36 Semba RD, Ferrucci L, Bartali B. et al. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern Med 2014; 174: 1077-1084 DOI: 10.1001/jamainternmed.2014.1582. (PMID: 24819981)
• 37 Timmers S, de Ligt M, Phielix E. et al. Resveratrol as Add-on Therapy in Subjects With Well-Controlled Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care 2016; 39: 2211-2217 DOI: 10.2337/dc16-0499. (PMID: 27852684)
• 38 Brasnyo P, Molnar GA, Mohas M. et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106: 383-389 DOI: 10.1017/S0007114511000316. (PMID: 21385509)
• 39 Dutta P, Courties G, Wei Y. et al. Myocardial infarction accelerates atherosclerosis. Nature 2012; 487: 325-329 DOI: 10.1038/nature11260. (PMID: 22763456)
• 40 Tawakol A, Fayad ZA, Mogg R. et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. Journal of the American College of Cardiology 2013; 62: 909-917 DOI: 10.1016/j.jacc.2013.04.066. (PMID: 23727083)